newsfilter
← Latest News
GlobeNewswire·

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary